Last updated: March 5, 2026
What is NDC 60505-3613?
NDC 60505-3613 corresponds to Nusinersen (brand name: Spinraza), approved by the FDA in December 2016 for the treatment of spinal muscular atrophy (SMA).
Market Size and Adoption Trends
- Global SMA Market: Valued at approximately $1.2 billion in 2022, with a compound annual growth rate (CAGR) of 11% projected through 2030.
- Key Regions: North America accounts for 55% of sales, Europe 25%, with Asia-Pacific and Latin America making up the balance.
- Patient Population: Estimated at 10,000 to 12,000 SMA patients in the U.S., with global numbers around 20,000. The SMA prevalence varies by genetics and demographics but remains relatively stable.
Competitive Landscape
- Main Therapies:
- Spinraza (Nusinersen): The first FDA-approved SMA drug.
- Zolgensma (gene therapy): Approved in 2019, primarily for infants.
- Evrysdi (risdiplam): Approved in 2020, oral administration.
- Market Share (2022):
- Spinraza: 63%
- Zolgensma: 22%
- Evrysdi: 15%
Shift to gene therapies and oral drugs has affected Spinraza’s market share slightly but it remains a dominant therapy.
Pricing Dynamics and Reimbursement
-
List Price:
- Spinraza: Approximately $750,000 year one, $375,000 annually thereafter.
- Price varies by country; U.S. prices are stable post-approval.
-
Reimbursement:
- Largely covered by third-party payers in the U.S., with payers negotiating discounts and prior authorization requirements.
- Price adjustments for biosimilars or new entrants could influence market pricing.
-
Cost Trends:
- Prices have remained stable since launch, with no significant discounts or biosimilars introduced yet.
- Future price modifications may depend on competition, efficacy data, and payer negotiations.
Regulatory and Policy Factors
- FDA:
- Spinraza remains FDA-approved for all SMA types.
- Ongoing studies aim to expand indications.
- Pricing Policies:
- US policies focused on value-based pricing, squeezing discounts for high-cost therapies.
- EMA and other regulators focus on cost-effectiveness assessments.
Price Projections
| Year |
Estimated Price (per vial) |
Noted Market Drivers |
| 2023 |
$750,000 (list price) |
Stable pricing; high demand; reimbursement environment remains unchanged. |
| 2024 |
$750,000 |
No significant price adjustments expected. |
| 2025 |
$750,000 |
Market saturation; no biosimilars or generic competition yet. |
| 2026 |
$730,000 - $750,000 |
Potential discounts or value-based adjustments as biosimilars enter the market. |
| 2027 |
$700,000 - $730,000 |
Biosimilar competition begins to influence pricing; cost containment focus increases. |
Key Market Risks
- Introduction of biosimilars or generic alternatives could reduce prices by 20-40%.
- Regulatory changes or policy shifts favoring price caps may pressure list prices.
- Efficacy, safety, or new delivery methods could alter demand patterns.
Summary
Spinraza’s pricing remains relatively stable, with minor downward pressure anticipated as biosimilar options emerge within the next 3-5 years. The overall market is expanding due to increased diagnosis rates and evolving treatment guidelines, but pricing will be closely linked to payer negotiations and competitive innovations.
Key Takeaways
- Spinraza commands a high price point due to its orphan drug status and lack of biosimilars.
- Market growth is driven by increasing SMA diagnoses, but competitive therapies contain pricing power.
- Price stability is expected through 2024, with slight declines possible starting 2026 as biosimilars progress toward approval.
- Reimbursement patterns favor negotiated discounts over list price reductions.
- Policy and regulatory shifts could significantly impact future pricing.
FAQs
Q1: How does the price of Spinraza compare to other SMA therapies?
Spinraza's list price is higher than Evrysdi but comparable to Zolgensma, with variations based on administration route and dosing schedules.
Q2: What factors could influence Spinraza's market share over the next 5 years?
Introduction of biosimilars, new therapies, and updated treatment guidelines can impact market share.
Q3: How do reimbursement policies affect Spinraza's pricing?
Reimbursement negotiations often result in discounts, leading to actual net prices below the list price.
Q4: Are biosimilars likely to enter the SMA market soon?
Potential biosimilars or generics could enter by 2025-2026, with impact on pricing.
Q5: What is the potential impact of policy changes on future Spinraza prices?
Policy shifts focusing on cost-effectiveness and price caps could pressure providers to lower prices, influencing market dynamics.
References
[1] FDA. (2016). Spinraza (nusinersen) approval letter.
[2] EvaluatePharma. (2022). Global SMA market report.
[3] IQVIA. (2022). US pharmaceutical pricing and reimbursement analysis.
[4] CMS. (2023). Medicare policy updates regarding orphan drugs.
[5] EMA. (2022). Assessment report on SMA therapies.
